NHS England Admits Delay in Clinical Trial on Puberty Blocking Drugs
NHS England has disclosed a delay in the recruitment of patients for the first clinical trial assessing the impact of puberty blocking drugs, pushing the start date to early next year. The trial, initially scheduled to begin later this year, aims to study the potential advantages and risks of puberty suppressing hormones for young individuals exploring their gender identity.
The trial has gained attention following Dr. Hilary Cass’s review, which raised concerns about the unproven nature of puberty blockers and their potential harm. Despite the Conservative government’s ban on these drugs, NHS England plans to enroll patients in a study recommended by Cass, sparking debate on the ethical implications.
Advocates like Naomi Cunningham from Sex Matters oppose the trials due to known risks to fertility and overall health. However, organizations like Mermaids advocate for more support for transgender youth, criticizing recent restrictions on puberty blockers.
As NHS England proceeds with the trial, the controversy surrounding its use and treatment of under-18s with gender incongruence intensifies.
[ad_2]
Source link
